Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q1 2021 · 10-Q
Revenue$1.59M$1.59M+299.7% vs Q1 2020 Net Income-$180.00K-$180.00KN/M vs Q1 2020 EPS Diluted$0.00$0.00N/M vs Q1 2020 Gross Profit$950,000+292.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flow-$199,000N/M Free Cash Flowderived-$373,000— Margins · derivedGross margin59.7%−1.1 pt vs Q1 2020
Operating margin-11.3%+272.7 pt vs Q1 2020
Net margin-11.3%+271.3 pt vs Q1 2020
ended Oct 31, 2020 · filed Dec 15, 2020 · 45 d after period end